- Number of Upgrades from Top-Ranked Analysts
- 4 (in the last 90 days)
- Consensus Rating
- Buy
- Rating Score
- 3.3
- Ratings Breakdown
- 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $11.33 (1,400.9% Upside)
About Invivyd
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
Read More
Recent Analyst Ratings